Bladder cancer: A disease ripe for major advances

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 12, 2014, Pages 838-845

  Park, Jong Chul ^a,b   Hahn, Noah M ^a,b  

^a UNIVERSITY OF BALTIMORE   (United States)

^b Genitourinary oncology fellow ^*  (United States)

Author keywords

Bladder cancer; Immunotherapy; Molecular diagnostics; Novel opportunities; Targeted therapy

Indexed keywords

AFATINIB; APATORSEN; BEVACIZUMAB; BUPARLISIB; CABOZANTINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOVITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; GEMCITABINE; HEAT SHOCK PROTEIN 27; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; SUNITINIB; TEMSIROLIMUS; VANDETANIB; VASCULOTROPIN RECEPTOR; DNA; MICRORNA;

ADENOCARCINOMA; ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); FUNDING; HUMAN; MOLECULAR DIAGNOSTICS; MUSCLE INVASIVE BLADDER CANCER; MYCOBACTERIUM BOVIS BCG; NON MUSCLE INVASIVE BLADDER CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; ANIMAL; BLOOD; DISEASE MODEL; FINANCIAL MANAGEMENT; GENETICS; IMMUNOTHERAPY; MEDICAL RESEARCH; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR EMBOLISM; URINARY BLADDER NEOPLASMS;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DNA, NEOPLASM; HUMANS; IMMUNOTHERAPY; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RESEARCH DESIGN; RESEARCH SUPPORT AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 84919922749     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3):289-293.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
3. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315-1330.
4. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006;68(3):549-553.
5. Sio TT, Ko J, Gudena VK, Verma N, Chaudhary UB. Chemotherapeutic and targeted biological agents for metastatic bladder cancer: A comprehensive review. Int J Urol. 2014;21(7):630-637.
6. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009;3(6)(suppl 4):S193-S198.
7. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-465.
8. Raghavan D. Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urol Oncol. 2003;21(6):468-474.
9. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-866.
10. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-675.
11. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068-3077.
12. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer. 1989;64(12):2448-2458.
13. de Wit R; European Organization for Research and Treatment. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer. 2003;97(8)(suppl):2120-2126.
14. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-4608.
15. Kaplan AL, Litwin MS, Chamie K. The future of bladder cancer care in the USA. Nat Rev Urol. 2014;11(1):59-62.
16. Williamson JM, Jones IH, Hocken DB. How does the media profile of cancer compare with prevalence? Ann R Coll Surg Engl. 2011;93(1):9-12.
17. Soloway MS. Bladder carcinoma: where are the patient advocates? Cancer. 2005;104(8):1559-1562.
18. Lotan Y, Kamat AM, Porter MP, et al; Bladder Cancer Think Tank; Bladder Cancer Advocacy Network; Society of Urologic Oncology. Key concerns about the current state of bladder cancer: A position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer. 2009;115(18):4096-4103.
19. Carter AJ, Nguyen CN. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health. 2012;12(1):526.
20. FY 2013 research funding by cancer type. National Cancer Institute. http://fundedresearch.cancer.gov/nciportfolio/search/funded?type=site&fy=PUB2013. Accessed November 7, 2014.
21. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-218.
22. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-322.
23. Naoe M, Ogawa Y, Morita J, et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer. 2007;109(7):1439-1445.
24. Flaig TW, Wilson S, van Bokhoven A, et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology. 2011;78(4):863-867.
25. Gallagher DJ, Milowsky MI, Ishill N, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol. 2009;20(2):305-308.
26. Gazzaniga P, Gradilone A, de Berardinis E, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: A CellSearch analysis. Ann Oncol. 2012;23(9):2352-2356.
27. Raimondi C, Gradilone A, Gazzaniga P. Circulating tumor cells in early bladder cancer: insight into micrometastatic disease. Expert Rev Mol Diagn. 2014;14(4):407-409.
28. Nezos A, Pissimisis N, Lembessis P, et al. Detection of circulating tumor cells in bladder cancer patients. Cancer Treat Rev. 2009;35(3):272-279.
29. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007;635(2-3):105-117.
30. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in earlyand late-stage human malignancies. Sci Transl Med. 2014;6(224):224-324.
31. Siolas D, Hannon GJ. Patient-derived tumor xenografts: Transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315-5319.
32. Knapp DW, Glickman NW, Denicola DB, Bonney PL, Lin TL, Glickman LT. Naturally-occurring canine transitional cell carcinoma of the urinary bladder: A relevant model of human invasive bladder cancer. Urol Oncol. 2000;5(2):47-59.
33. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA. 2007;104(32):13086-13091.
34. Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4(10):1140-1153.
35. Plimack ER, Dunbrack R, Brennan T, et al. Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblas-tine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive bladder cancer (MIBC) [ASCO abstract 4538]. J Clin Oncol. 2014;32(15)(suppl):4538.
36. De Boer EC, De Jong WH, Van Der Meijden AP, et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother. 1991;33(6):411-416.
37. Alexandroff AB, Nicholson S, Patel PM, Jackson AM. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy. 2010;2(4):551-560.
38. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer. 1992;29A(1):69-75.
39. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104(10):3967-3972.
40. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
41. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046-2054.
42. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB. Targeted therapies in urothelial carcinoma. Curr Opin Oncol. 2014;26(3):305-320.
43. Powles T, Vogelzang NJ, Fine GD, et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC) [ASCO abstract 5011]. J Clin Oncol. 2014;32(15)(suppl):5011.
44. Bajorin DF, Gomella LG, Sharma P, et al. Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence [ASCO abstract 4541]. J Clin Oncol. 2014;32(15)(suppl):4541.
45. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NYESO-1 protein plus BCG and GM-CSF. J Immunother. 2008;31(9):849-857.
46. Honma I, Kitamura H, Torigoe T, et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother. 2009;58(11):1801-1807.
47. Matsumoto K, Noguchi M, Satoh T, et al. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int. 2011;108(6):831-838.
48. Bambury RM, Rosenberg JE. Advanced urothelial carcinoma: overcoming treatment resistance through novel treatment approaches. Front Pharmacol. 2013;4:3.
49. Dreicer R. The future of drug development in urothelial cancer. J Clin Oncol. 2012;30(5):473-475.
50. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013;31(15):1834-1841.
51. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44-53.
52. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res. 2012;18(3):638-644.
53. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov. 2013;12(5):358-369.